Rhythm Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-02-01
- Employees
- 226
- Market Cap
- -
- Website
- http://www.rhythmtx.com
- Introduction
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Clinical Trials
72
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (67 trials with phase data)• Click on a phase to view related trials
A Single-center Study of Setmelanotide in Patients With Prader-Willi Syndrome
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06772597
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
- Conditions
- Hypothalamic ObesityMultiple Pituitary Hormone Deficiency Genetic FormSepto-Optic DysplasiaOptic Nerve HypoplasiaChildhood-onset Combined Pituitary Hormone DeficiencyPituitary Stalk Interruption Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT06760546
Open-Label Extension Study of Setmelanotide
- Conditions
- Obesity Associated With Defects in Leptin-melanocortin Pathway
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06596135
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸UC San Diego- Rady Children's Hospital, San Diego, California, United States
🇺🇸University of Florida at Gainesville, Gainesville, Florida, United States
A Study of RM-718 in Healthy Subjects and in Patients With HO
- Conditions
- Hypothalamic Obesity
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06239116
- Locations
- 🇺🇸
UAB Pediatric Endocrinology, Birmingham, Alabama, United States
🇺🇸Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06046443
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next